These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. von Bonsdorff M; Sipilä R; Pitkänen E Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470 [TBL] [Abstract][Full Text] [Related]
4. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620 [TBL] [Abstract][Full Text] [Related]
5. [Aluminum poisoning]. Cervar M; Stavljenic A; Vukicević S Lijec Vjesn; 1989; 111(4-5):164-9. PubMed ID: 2671563 [TBL] [Abstract][Full Text] [Related]
6. [The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy]. Válek A; Sulková S; Laurinová Z Ter Arkh; 1991; 63(6):89-93. PubMed ID: 1948757 [No Abstract] [Full Text] [Related]
7. The efficacy of various treatment modalities on aluminium associated bone disease. Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. McCarthy JT; Milliner DS; Johnson WJ Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295 [TBL] [Abstract][Full Text] [Related]
9. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553 [TBL] [Abstract][Full Text] [Related]
10. Aluminum-related osteomalacia in renal-failure patients. Vick KE; Johnson CA Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471 [TBL] [Abstract][Full Text] [Related]
11. [Aluminum poisoning in dialysis patients--diagnosis and therapy]. Vogelsang U Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059 [TBL] [Abstract][Full Text] [Related]
13. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis]. Wang G; Zhu P; Wang S Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645 [TBL] [Abstract][Full Text] [Related]
15. Desferrioxamine in the treatment of aluminum overload. Ackrill P; Day JP Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106 [TBL] [Abstract][Full Text] [Related]
16. [Aluminum osteopathy--experience with therapy]. Sulková S Vnitr Lek; 1993 May; 39(5):459-63. PubMed ID: 8351877 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients. Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356 [TBL] [Abstract][Full Text] [Related]
19. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky IB; Foley J; Nelson P; Goodman WG N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306 [TBL] [Abstract][Full Text] [Related]
20. Changes in bone histology after treatment with desferrioxamine. Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986 [No Abstract] [Full Text] [Related] [Next] [New Search]